| dc.contributor.author | Pan American Health Organization | |
| dc.date.accessioned | 2020-09-21T19:34:34Z | |
| dc.date.available | 2020-09-21T19:34:34Z | |
| dc.date.issued | 2020-07-16 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/2187 | |
| dc.description.abstract | PAHO does not recommend oral or parenteral use of chlorine dioxide or sodium chlorite-based products for patients with suspected or diagnosed COVID-19 or for anyone else. There is no evidence of their effectiveness and the ingestion or inhalation of such products could cause serious adverse effects. | |
| dc.language | English | |
| dc.subject | Infecctious Diseases | |
| dc.subject | COVID-19 | |
| dc.subject | Coronavirus | |
| dc.title | PAHO Does Not Recommend Taking Products that Contain Chlorine Dioxide, Sodium Chlorite, Sodium Hypochlorite, or Derivatives, 16 July 2020 | |
| eihealth.country | Regional, Americas (PAHO/OPS) | |
| eihealth.category | Infection prevention and control, including health care workers protection | |
| eihealth.type | WHO/PAHO Guidance | |
| eihealth.maincategory | Slow Spread / Reducir la Dispersión | |
